Open account
Sign up/Log in
News
NKTX
7.56
+2.30%
0.17
Weekly Report: what happened at NKTX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at NKTX last week (0408-0412)?
Weekly Report · 04/15 09:29
12 Health Care Stocks Moving In Friday's Pre-Market Session
PaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. Allarity Therapeutics stock increased by 55.84% and HCW Biologics shares increased by 20.77%. Losers Motus GI Hldgs stock fell 26.1% during the session.
Benzinga · 04/12 12:09
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveiled plans to expand clinical development for its lead program, CNTY-101. The company plans to pursue additional autoimmune disease indications in 2024. Century also announced the acquisition of Clade Therapeutic Inc. Century is a CD19-targeting iNK cell therapy for cancer and autoimmune diseases.
Benzinga · 04/11 20:24
Nkarta Price Target Maintained With a $15.00/Share by Needham
Dow Jones · 04/10 11:42
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)
TipRanks · 04/10 11:00
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)
TipRanks · 04/10 06:30
Weekly Report: what happened at NKTX last week (0401-0405)?
Weekly Report · 04/08 09:31
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Nkarta, Inc. Investors concerning the Company’s possible violations of federal securities laws. On March 21, 2024, nkarta announced that it had “deprioritized” its acute myeloid leukemia program. The stock price fell $4.06, or 31.3%, on March 22, 2024.
Barchart · 04/05 16:44
Weekly Report: what happened at NKTX last week (0325-0329)?
Weekly Report · 04/01 09:31
Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-hearted
TipRanks · 03/26 18:59
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
TipRanks · 03/26 11:25
Nkarta Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/26 11:17
Nkarta Price Target Raised to $16.00/Share From $15.00 by Canaccord Genuity
Dow Jones · 03/26 11:17
Canaccord Genuity Maintains Buy on Nkarta, Raises Price Target to $16
Benzinga · 03/26 11:07
Stifel Nicolaus Keeps Their Buy Rating on Nkarta (NKTX)
TipRanks · 03/26 02:05
Nkarta: NK Cell Therapy Advancement On Two Fronts
Nkarta, Inc. Is gearing up to report results from its phase 1 study using NKX019 for the treatment of patients with relapsed/refractory non-Hodgkin's lymphoma. The company is also advancing its allogeneic NK cell to treat patients with autoimmune disorders like Lupus Nephritis. The first patient is expected to be dosed in the 1st half of 2024. NKx019 is being used to target patients with the global non-hodgkins's lymphoma market expected to reach $20 billion by 2036.
Seeking Alpha · 03/25 20:03
Nasdaq Turns Higher; Akanda Shares Plunge
U.S. Stocks traded mixed toward the end of trading on Monday. The Dow traded down 0.37% while the Nasdaq Composite turned higher. Energy shares jumped by 1% on Monday; industrials shares fell by 0.5%. Sales of new single-family houses in the U.S., fell by 662,000 in February. Asian markets closed lower; European shares mostly higher.
Benzinga · 03/25 19:00
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Landos Biopharma, Inc. Shares jumped 171.2% to $21.70 on Monday. AbbVie and Landos signed a definitive agreement to acquire the company. Altamira Therapeutics Ltd. Shares climbed 70.1% after falling around 22% on Friday. GameStop Corp. Shares rose 8.4% after the company announced a separation.
Benzinga · 03/25 18:44
12 Health Care Stocks Moving In Monday's Intraday Session
Landos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The company's, Q4 earnings report came out 2 days ago. Sagimet Biosciences ( NASDAQ:SGMT) and XTL Biopharmaceuticals also moved upwards. Trxade Health stock decreased by 48.6% during the regular session to $12.38.
Benzinga · 03/25 17:30
More
Webull provides a variety of real-time NKTX stock news. You can receive the latest news about Nkarta, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.